Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/2423
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | GORDON, Pedro Caldana | - |
dc.contributor.author | XAVIER, Josefa Cynara | - |
dc.contributor.author | LOUZA, Mario Rodrigues | - |
dc.date.accessioned | 2013-09-23T16:55:12Z | - |
dc.date.available | 2013-09-23T16:55:12Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.9, p.133-138, 2013 | - |
dc.identifier.issn | 1176-6328 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2423 | - |
dc.description.abstract | Background: In the last few decades, a large number of studies have produced compelling evidence that patients with schizophrenia are at increased risk for developing several medical conditions and diseases, including obesity, metabolic disturbances, and cardiovascular diseases. Several protocols have been designed with the aim of reducing such risk. Objective: To investigate current physical health status in a population of outpatients with schizophrenia. Methods: A cross-sectional study was conducted in our outpatient clinic, selecting subjects who met DSM-IV diagnosis criteria for schizophrenia. Data were collected regarding clinical characteristics, lifestyle, medication in use, and biometric and laboratory parameters. Results: A total of 261 patients were included. We found a high prevalence of elevated body mass index (BMI > 25) (70%), dyslipidemia (73.2%), and metabolic syndrome (28.7%). Patients' ages were associated with worsened lipid profiles, but other variables, such as disorder duration or type of antipsychotic in use, were not associated with any metabolic disturbance. Despite the increased prevalence of these conditions, only a small portion of the sample was under regular medical treatment. Conclusion: Outpatients with schizophrenia show signs of poor physical health conditions. These findings reinforce the need for an intensive and appropriate approach to assure that these patients receive adequate clinical referral and treatment. | - |
dc.language.iso | eng | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.relation.ispartof | Neuropsychiatric Disease and Treatment | - |
dc.rights | openAccess | - |
dc.subject | psychosis | - |
dc.subject | public health | - |
dc.subject | antipsychotic drugs | - |
dc.subject | cardiovascular disorders | - |
dc.subject.other | atypical antipsychotics | - |
dc.subject.other | catie schizophrenia | - |
dc.subject.other | prevalence | - |
dc.subject.other | mortality | - |
dc.subject.other | illness | - |
dc.subject.other | obesity | - |
dc.subject.other | risk | - |
dc.subject.other | dyslipidemia | - |
dc.subject.other | metaanalysis | - |
dc.subject.other | cholesterol | - |
dc.title | Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia | - |
dc.type | article | - |
dc.rights.holder | Copyright DOVE MEDICAL PRESS LTD | - |
dc.identifier.doi | 10.2147/NDT.S37019 | - |
dc.identifier.pmid | 23355783 | - |
dc.subject.wos | Clinical Neurology | - |
dc.subject.wos | Psychiatry | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.description.beginpage | 133 | - |
hcfmusp.description.endpage | 138 | - |
hcfmusp.description.volume | 9 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84872859043 | - |
hcfmusp.origem.id | WOS:000313578800001 | - |
hcfmusp.publisher.city | ALBANY | - |
hcfmusp.publisher.country | NEW ZEALAND | - |
hcfmusp.relation.reference | Allison DB, 1999, AM J PSYCHIAT, V156, P1686 | - |
hcfmusp.relation.reference | Bakx JC, 2000, PREV MED, V30, P138, DOI 10.1006/pmed.1999.0608 | - |
hcfmusp.relation.reference | Barnett AH, 2007, J PSYCHOPHARMACOL, V21, P357, DOI 10.1177/0269881107075509 | - |
hcfmusp.relation.reference | Brown S, 1997, BRIT J PSYCHIAT, V171, P502, DOI 10.1192/bjp.171.6.502 | - |
hcfmusp.relation.reference | Daumit GL, 2008, SCHIZOPHR RES, V105, P175, DOI 10.1016/j.schres.2008.07.006 | - |
hcfmusp.relation.reference | De Hert M, 2011, WORLD PSYCHIATRY, V10, P52 | - |
hcfmusp.relation.reference | De Hert M, 2008, SCHIZOPHR RES, V101, P295, DOI 10.1016/j.schres.2008.01.028 | - |
hcfmusp.relation.reference | De Hert M, 2011, WORLD PSYCHIATRY, V10, P138 | - |
hcfmusp.relation.reference | Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486 | - |
hcfmusp.relation.reference | Gigante DP, 2009, REV SAUDE PUBL, V43, P83, DOI 10.1590/S0034-89102009000900011 | - |
hcfmusp.relation.reference | Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404 | - |
hcfmusp.relation.reference | Hennekens CH, 2005, AM HEART J, V150, P1115, DOI 10.1016/j.ahj.2005.02.007 | - |
hcfmusp.relation.reference | Leitao-Azevedo CL, 2006, REV BRAS PSIQUIATR, V28, P301, DOI 10.1590/S1516-44462006005000016 | - |
hcfmusp.relation.reference | Leucht S, 2007, ACTA PSYCHIAT SCAND, V116, P317, DOI 10.1111/j.1600-0447.2007.01095.x | - |
hcfmusp.relation.reference | Leucht S, 2009, LANCET, V373, P31, DOI [10.1016/S0140-6736(08)61764-X, 10.1016/S01406736(08)61764-X] | - |
hcfmusp.relation.reference | Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688 | - |
hcfmusp.relation.reference | Majadas S, 2012, COMPR PSYCHIAT, V53, P145, DOI 10.1016/j.comppsych.2011.03.009 | - |
hcfmusp.relation.reference | Meyer JM, 2008, SCHIZOPHR RES, V101, P273, DOI 10.1016/j.schres.2007.12.487 | - |
hcfmusp.relation.reference | Millen BA, 2011, J PSYCHOPHARMACOL, V25, P639, DOI 10.1177/0269881110370505 | - |
hcfmusp.relation.reference | Misawa F, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-118 | - |
hcfmusp.relation.reference | Mitchell AJ, 2012, PSYCHOL MED, V42, P125, DOI 10.1017/S003329171100105X | - |
hcfmusp.relation.reference | Newcomer JW, 2005, CNS DRUGS, V19, P1 | - |
hcfmusp.relation.reference | Padmavati R, 2010, SCHIZOPHR RES, V121, P199, DOI 10.1016/j.schres.2010.05.010 | - |
hcfmusp.relation.reference | Ratliff' JC, 2012, COMPR PSYCHIAT, V53, P1028, DOI 10.1016/j.comppsych.2012.02.003 | - |
hcfmusp.relation.reference | Rummel-Kluge C, 2010, SCHIZOPHR RES, V123, P225, DOI 10.1016/j.schres.2010.07.012 | - |
hcfmusp.relation.reference | Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123 | - |
hcfmusp.relation.reference | Smith M, 2008, BRIT J PSYCHIAT, V192, P406, DOI 10.1192/bjp.bp.107.037184 | - |
hcfmusp.relation.reference | Teixeira PJR, 2007, REV BRAS PSIQUIATR, V29, P330, DOI 10.1590/S1516-44462007000400007 | - |
hcfmusp.relation.reference | Tran E, 2009, CANCER, V115, P3555, DOI 10.1002/cncr.24383 | - |
hcfmusp.relation.reference | Vancampfort D, 2012, PSYCHIAT RES | - |
hcfmusp.relation.reference | American Psychiatric Association, 1994, DIAGN STAT MAN MENT | - |
dc.description.index | PubMed | - |
hcfmusp.citation.scopus | 8 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GORDON_Weight_gain_metabolic_disturbances_and_physical_health_care_2013.PDF | publishedVersion (English) | 197.13 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.